Fosun Pharma gains approval for kidney disease drug

Shanghai Fosun Pharmaceutical Group (SSE:600196) announced that its subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., has received approval from the National Medical Products Administration for its licensed product, Tenapanor Hydrochloride Tablets, branded as "Wan Ti Le," for treating hyperphosphatemia in adult dialysis patients with chronic kidney disease (CKD). Separately, Fosun announced that its subsidiary, Suzhou Erye Pharmaceutical Co., Ltd., obtained drug registration approval for Compound Picosulfate Sodium Granules for bowel preparation before colonoscopy. Additionally, Fosun Pharma announced that its subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., has received acceptance for its drug registration application for Bromhexine Hydrochloride Injection, which will be used to treat phlegm for patients who have lung infections.